Navigation Links
Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
Date:11/6/2007

BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced today data from two studies of the company's ELAD(R) (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which was held November 2-6 in Boston, Mass.

-- Abstract (#91), "Interim results of Randomized Controlled Trial of

ELAD(R) in Acute on Chronic Liver Disease," was presented in a

parallel session on Monday, November 5th. This controlled, randomized

(2:1) clinical trial enrolled 69 patients with acute-on-chronic liver

failure in two protocols at two centers in Beijing, China. The first

49 patient protocol resulted in a 30 day transplant-free survival rate

of 50% in the controls and 87% in the treated group (p<0.01). The

second protocol, which had a shorter ELAD(R) treatment time, did not

reach statistical significance. Initial conclusions from this trial

demonstrated ELAD(R) is safe and effective in this patient population

when used with the longer treatment time.

-- Abstract (#855), "ELAD(R) Cellular and System Performance

Improvements," was a poster presentation detailing the metabolic

characteristics of the ELAD(R) cartridges in order to optimize

performance.

Terry Winters, Ph.D., Chairman and CEO said, "These data are consistent with our previous research and experience. ELAD is helping patients and the technology continues to be refined for optimum benefit. These are positive developments as we apply for marketing approval in China and advance our U.S. clinical program."

To date, only liver transplantation has been shown to increase survival. However, demand for liver transplantation far exceeds the supply of donor livers, creating a need for an alternative, lifesaving therapy such as ELAD(R). In China alone, an estimated 160 million
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... today announced that Tom Ryan , Chairman, President and CEO, and Per Lofberg , Executive Vice President ... Healthcare Conference on March 23, 2010 . The Company is scheduled to speak at approximately 9:00 a.m. ... ... , , ...
... Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that it ... June 3, 2010 , in Rockville, Maryland .  The record ... .  Only stockholders of record at the close of business on ... any adjournment thereof.  Vanda anticipates mailing its proxy statement in ...
Cached Medicine Technology:CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 2CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 3Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders 2
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... 12 June 2009: After five years of receiving infliximab ... (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, ... five years, 78.4% of AS patients had no arthritis ... between tendon and bone). Over this period, patients continued ...
... The board of directors of Abbott today declared a quarterly common dividend ... 342nd consecutive quarterly dividend to be paid by Abbott since 1924. ... at the close of business on July 15, 2009. , , ... an 11 percent increase earlier this year - and was again named ...
... CHICAGO, June 12 Germany remains an attractive investment,location ... states.,This is in large part due to the robust ... American investor interest in,Germany remains steady, as confirmed by ... success stories at the "How,Far East? Eastern Germany: The ...
... Medifast, Inc. (NYSE: MED ) today announced that ... Medifast Weight Control Centers. Earlier in the year, the Company ... and analyze the success of the model throughout the year. ... expanding its investment in this area. , , Despite ...
... Travelers Turn to InsureMyTrip.com for Coverage Protection and Information ... ,the scientific criteria for an influenza pandemic have been ... the A(H1N1) virus, commonly referred to as Swine Flu, ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly in ...
... of the University of Southern California (USC) have identified ... to breakan occurrence that marks the first step in ... researchers with the clearest insight yet into why these ... chromosome, says principal investigator Michael R. Lieber, M.D., Ph.D., ...
Cached Medicine News:Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
Medicine Products: